Technical Analysis for ICPT - Intercept Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 118.85 -0.43% -0.51
ICPT closed down 0.43 percent on Thursday, September 20, 2018, on 74 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ICPT trend table...

Date Alert Name Type % Chg
Sep 20 NR7 Range Contraction 0.00%
Sep 20 Multiple of Ten Bearish Other 0.00%
Sep 20 Inside Day Range Contraction 0.00%
Sep 19 Upper Bollinger Band Walk Strength -0.43%
Sep 19 Multiple of Ten Bearish Other -0.43%
Sep 19 Upper Bollinger Band Touch Strength -0.43%
Sep 18 New 52 Week Closing High Bullish -1.45%
Sep 18 Pocket Pivot Bullish Swing Setup -1.45%
Sep 18 Upper Bollinger Band Walk Strength -1.45%
Sep 18 Multiple of Ten Bullish Other -1.45%

Older signals for ICPT ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.
Is ICPT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 124.4
52 Week Low 51.05
Average Volume 472,757
200-Day Moving Average 77.056
50-Day Moving Average 105.8112
20-Day Moving Average 113.6915
10-Day Moving Average 117.329
Average True Range 3.9397
ADX 36.23
+DI 29.387
-DI 8.2033
Chandelier Exit (Long, 3 ATRs ) 112.5809
Chandelier Exit (Short, 3 ATRs ) 114.8991
Upper Bollinger Band 122.3663
Lower Bollinger Band 105.0167
Percent B (%b) 0.8
BandWidth 15.260244
MACD Line 4.0859
MACD Signal Line 3.882
MACD Histogram 0.2039
Fundamentals Value
Market Cap 2.98 Billion
Num Shares 25.1 Million
EPS -15.49
Price-to-Earnings (P/E) Ratio -7.67
Price-to-Sales 20.99
Price-to-Book 8.77
PEG Ratio -0.61
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 121.97
Resistance 3 (R3) 122.27 121.52 121.45
Resistance 2 (R2) 121.52 120.73 121.38 121.28
Resistance 1 (R1) 120.19 120.24 119.82 119.89 121.10
Pivot Point 119.44 119.44 119.26 119.30 119.44
Support 1 (S1) 118.11 118.65 117.74 117.81 116.60
Support 2 (S2) 117.36 118.16 117.22 116.42
Support 3 (S3) 116.03 117.36 116.25
Support 4 (S4) 115.73